Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences
Key Highlights
- ➤Nuwellis (NUWE) to participate in four October medical conferences across pediatrics, critical care, and heart failure
- ➤Aquadex SmartFlow targets fluid overload unresponsive to medical management, including diuretics
- ➤Aquadex is indicated for temporary or extended ultrafiltration in adult and pediatric patients weighing 20 kilograms or more
- ➤ASN Kidney Week 2026 expected to bring together over 12,000 kidney professionals
Expert Statements
Mike McCormick, President and Chief Executive Officer of Nuwellis
“Pediatrics, critical care, and heart failure are the three key growth markets for Nuwellis, and fluid overload is a common and complex challenge across each of these patient populations.”
Mike McCormick, President and Chief Executive Officer of Nuwellis
“By engaging clinicians and specialists at leading meetings across all three markets, we are advancing our commercial strategy while increasing awareness of Aquadex and its ability to provide precise, adjustable fluid removal when conventional approaches may be insufficient.”
Mike McCormick, President and Chief Executive Officer of Nuwellis
“These conferences give us an important opportunity to deepen relationships with the specialists caring for patients who can benefit from more individualized fluid management.”
MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced its participation in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. Across the events, Nuwellis will engage directly with clinicians on the challenge of fluid overload and the role of its Aquadex SmartFlow(®) system in providing precise, controlled fluid removal for patients who require individualized fluid management.
“Pediatrics, critical care, and heart failure are the three key growth markets for Nuwellis, and fluid overload is a common and complex challenge across each of these patient populations,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “By engaging clinicians and specialists at leading meetings across all three markets, we are advancing our commercial strategy while increasing awareness of Aquadex and its ability to provide precise, adjustable fluid removal when conventional approaches may be insufficient. These conferences give us an important opportunity to deepen relationships with the specialists caring for patients who can benefit from more individualized fluid management.”
Get started
Create a free account to read the full story.